ChromaDex (NASDAQ:CDXC) Price Target Raised to $11.00

ChromaDex (NASDAQ:CDXC) had its price objective hoisted by HC Wainwright from $8.00 to $11.00 in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for ChromaDex’s Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.04 EPS, Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.29 EPS.

Other equities research analysts have also recently issued research reports about the company. StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH lifted their target price on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a report on Wednesday, March 5th.

ChromaDex Stock Down 0.9 %

CDXC stock opened at $7.83 on Monday. ChromaDex has a 52-week low of $1.98 and a 52-week high of $9.18. The stock’s fifty day simple moving average is $5.92 and its 200-day simple moving average is $5.28. The stock has a market capitalization of $608.78 million, a price-to-earnings ratio of 783.78 and a beta of 2.21.

Insider Buying and Selling at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.64% of the stock is currently owned by corporate insiders.

Institutional Trading of ChromaDex

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC purchased a new stake in shares of ChromaDex during the fourth quarter worth about $555,000. Two Sigma Investments LP purchased a new stake in shares of ChromaDex during the fourth quarter worth about $675,000. State of Wyoming purchased a new stake in shares of ChromaDex during the fourth quarter worth about $39,000. Sherbrooke Park Advisers LLC purchased a new stake in shares of ChromaDex during the fourth quarter worth about $94,000. Finally, ProShare Advisors LLC purchased a new stake in shares of ChromaDex during the fourth quarter worth about $74,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.